Compare KMT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KMT | MLYS |
|---|---|---|
| Founded | 1938 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.4B |
| IPO Year | 1994 | 2023 |
| Metric | KMT | MLYS |
|---|---|---|
| Price | $35.51 | $23.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $36.00 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 05-06-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $1,966,845,000.00 | N/A |
| Revenue This Year | $14.45 | N/A |
| Revenue Next Year | $7.95 | N/A |
| P/E Ratio | $48.92 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.30 | $10.44 |
| 52 Week High | $42.03 | $47.65 |
| Indicator | KMT | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 29.66 |
| Support Level | $33.93 | $13.42 |
| Resistance Level | $41.89 | $31.09 |
| Average True Range (ATR) | 1.84 | 1.77 |
| MACD | -0.63 | -0.26 |
| Stochastic Oscillator | 8.25 | 9.72 |
Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.